Buprenorphine/naloxone treatment practices in Malaysia: Results of national surveys of physicians and patients

Vicknasingam B 1 , Dazali MN 2 , Singh D 3 , Schottenfeld RS 4 , Chawarski MC 5

Affiliations 

  • 1 Centre for Drug Research, Universiti Sains Malaysia, 11800 Penang, Malaysia. Electronic address: vickna@usm.my
  • 2 Centre for Drug Research, Universiti Sains Malaysia, 11800 Penang, Malaysia. Electronic address: nazridazali@gmail.com
  • 3 Centre for Drug Research, Universiti Sains Malaysia, 11800 Penang, Malaysia. Electronic address: darshan@usm.my
  • 4 Yale School of Medicine, New Haven, CT 06519, USA. Electronic address: richard.schottenfeld@yale.edu
  • 5 Yale School of Medicine, New Haven, CT 06519, USA. Electronic address: marek.chawarski@yale.edu
Drug Alcohol Depend, 2015 Jul 1;152:164-9.
PMID: 25935736 DOI: 10.1016/j.drugalcdep.2015.04.007

Abstract

Medication assisted treatment with buprenorphine/naloxone (Bup/Nx), including prescribing and dispensing practices of general practitioners (GPs) in Malaysia and their patients' experiences with this treatment have not been systematically examined. The current study surveyed GPs providing Bup/Nx treatment and patients receiving office-based Bup/Nx treatment in Malaysia.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications